Cargando…
Strong medicine : creating incentives for pharmaceutical research on neglected diseases /
"Vaccines offer the best hope for controlling diseases and could dramatically improve health in poor countries. But developers have little incentive to undertake the costly and risky research needed to develop vaccines. This is partly because the potential consumers are poor, but also because g...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Princeton, NJ :
Princeton University Press,
2004.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | JSTOR_ocn948756498 | ||
| 003 | OCoLC | ||
| 005 | 20231005004200.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 160505s2004 njua ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d IDEBK |d KIJ |d YDXCP |d EBLCP |d JSTOR |d YDX |d OCLCO |d P@U |d OCLCA |d OCLCQ |d IOG |d EZ9 |d OCLCQ |d OCLCO |d OCLCF |d TXC |d OCLCO |d INT |d OCLCA |d AU@ |d OCLCO |d IDB |d WYU |d OCLCQ |d OCLCO |d LVT |d OCLCQ |d OCLCA |d OCLCQ |d OCLCO |d OCLCA |d INARC |d MM9 |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCL |d OCLCO | ||
| 015 | |a GBA454970 |2 bnb | ||
| 016 | 7 | |a 101231472 |2 DNLM | |
| 016 | 7 | |a 012959209 |2 Uk | |
| 019 | |a 855717801 |a 951065147 |a 961005602 |a 965416957 |a 966768856 |a 1127570272 |a 1151318321 | ||
| 020 | |a 9781400880140 |q (electronic bk.) | ||
| 020 | |a 1400880149 |q (electronic bk.) | ||
| 020 | |z 0691121133 | ||
| 020 | |z 9780691121130 | ||
| 020 | |z 9780691171166 | ||
| 020 | |z 0691171165 | ||
| 024 | 8 | |a 99808804286 | |
| 029 | 1 | |a AU@ |b 000062362313 | |
| 029 | 1 | |a GBVCP |b 1003820824 | |
| 035 | |a (OCoLC)948756498 |z (OCoLC)855717801 |z (OCoLC)951065147 |z (OCoLC)961005602 |z (OCoLC)965416957 |z (OCoLC)966768856 |z (OCoLC)1127570272 |z (OCoLC)1151318321 | ||
| 037 | |a 22573/ctt1dr3bd9 |b JSTOR | ||
| 043 | |a d------ | ||
| 050 | 4 | |a RS122 |b .K74 2004eb | |
| 060 | 4 | |a 2004 L-294 | |
| 060 | 4 | |a QV 736 |b K92s 2004 | |
| 072 | 7 | |a POL |x 027000 |2 bisacsh | |
| 072 | 7 | |a POL |x 019000 |2 bisacsh | |
| 072 | 7 | |a BUS069030 |2 bisacsh | |
| 072 | 7 | |a BUS074000 |2 bisacsh | |
| 082 | 0 | 4 | |a 362.17/82/091724 |2 22 |
| 084 | |a 44.42 |2 bcl | ||
| 084 | |a VS 5350 |2 rvk | ||
| 049 | |a UAMI | ||
| 100 | 1 | |a Kremer, Michael, |d 1964- | |
| 245 | 1 | 0 | |a Strong medicine : |b creating incentives for pharmaceutical research on neglected diseases / |c Michael Kremer and Rachel Glennerster. |
| 264 | 1 | |a Princeton, NJ : |b Princeton University Press, |c 2004. | |
| 300 | |a 1 online resource (xiv, 153 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file | ||
| 504 | |a Includes bibliographical references (pages 127-143) and index. | ||
| 520 | 1 | |a "Vaccines offer the best hope for controlling diseases and could dramatically improve health in poor countries. But developers have little incentive to undertake the costly and risky research needed to develop vaccines. This is partly because the potential consumers are poor, but also because governments drive down prices." "In Strong Medicine, Michael Kremer and Rachel Glennerster offer an innovative yet simple solution to this worldwide problem: "Pull" programs to stimulate research. Here's how such programs would work. Funding agencies would commit to purchase viable vaccines if and when they were developed. This would create the incentives for vaccine developers to produce usable products for these neglected diseases. Private firms, rather than funding agencies, would pick which research strategies to pursue. After purchasing the vaccine, funders could distribute it at little or no cost to the afflicted countries."--Jacket | |
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Cover ; Title ; Copyright ; Dedication ; CONTENTS ; Foreword ; Acknowledgments ; 1. INTRODUCTION ; 2. HEALTH IN LOW-INCOME COUNTRIES ; The Disease Environment in Low-Income Countries ; Weak Health-Care Infrastructure ; Malaria, Tuberculosis, and HIV/AIDS. | |
| 505 | 8 | |a The Impact of Cheap, Simple Technologies 3. THE PAUCITY OF PRIVATE R & D TARGETED TO THE NEEDS OF LOW-INCOME COUNTRIES ; The Extent of R & D Targeted to Low-Income Countries ; The Scientific Potential for New Vaccines ; 4. MARKET AND GOVERNMENT FAILURES. | |
| 505 | 8 | |a Why Target Foreign Assistance to Vaccine R & D? The Patent Tradeoff ; Low-Income Countries and Intellectual Property ; Social versus Private Return: Some Quantitative Estimates ; The Role of Public Purchases ; 5. THE ROLE OF PUSH PROGRAMS. | |
| 505 | 8 | |a Meningococcal Meningitis: An Example of a Successful Push Program A Cautionary Tale: The USAID Malaria Vaccine Program ; Incentives under Push Programs ; 6. THE POTENTIAL ROLE OF PULL PROGRAMS ; The Effect of Market Size on Innovation ; The Impact of Financial Incentive Programs. | |
| 505 | 8 | |a Examples of Pull Programs Stimulating Research Advantages and Limitations of Pull Programs ; 7. PULL PROGRAMS: A MENU ; Commitments to Finance Purchase of Products and Patents ; Patent Extensions on Other Pharmaceuticals as Compensation for Vaccine Development ; Best-Entry Tournaments. | |
| 590 | |a JSTOR |b Books at JSTOR Demand Driven Acquisitions (DDA) | ||
| 590 | |a JSTOR |b Books at JSTOR All Purchased | ||
| 590 | |a JSTOR |b Books at JSTOR Evidence Based Acquisitions | ||
| 650 | 0 | |a Pharmacy |x Research |x Economic aspects |z Developing countries. | |
| 650 | 0 | |a Drugs |x Research |x Economic aspects |z Developing countries. | |
| 650 | 0 | |a Vaccines |x Research |x Economic aspects |z Developing countries. | |
| 650 | 0 | |a Drugs. | |
| 650 | 0 | |a Research. | |
| 650 | 0 | |a Vaccines. | |
| 650 | 0 | 2 | |a Developing Countries |
| 650 | 0 | 2 | |a Economics, Pharmaceutical |
| 650 | 0 | 2 | |a Pharmaceutical Preparations |
| 650 | 0 | 2 | |a Research Support |
| 650 | 0 | 2 | |a Research |
| 650 | 0 | 2 | |a Vaccines |
| 650 | 6 | |a Pharmacoéconomie. | |
| 650 | 6 | |a Médicaments. | |
| 650 | 6 | |a Recherche. | |
| 650 | 6 | |a Vaccins. | |
| 650 | 7 | |a research (function) |2 aat | |
| 650 | 7 | |a POLITICAL SCIENCE |x Public Policy |x Social Security. |2 bisacsh | |
| 650 | 7 | |a POLITICAL SCIENCE |x Public Policy |x Social Services & Welfare. |2 bisacsh | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Economics |x Theory. |2 bisacsh | |
| 650 | 7 | |a Vaccines |2 fast | |
| 650 | 7 | |a Research |2 fast | |
| 650 | 7 | |a Drugs |2 fast | |
| 650 | 7 | |a Drugs |x Research |x Economic aspects |2 fast | |
| 650 | 7 | |a Pharmacy |x Research |x Economic aspects |2 fast | |
| 651 | 7 | |a Developing countries |2 fast | |
| 650 | 7 | |a Gesundheitsförderung |2 gnd | |
| 650 | 7 | |a Arzneimittelforschung |2 gnd | |
| 650 | 7 | |a Forschungsförderung |2 gnd | |
| 650 | 7 | |a Forschungsfinanzierung |2 gnd | |
| 651 | 7 | |a Entwicklungsländer |2 gnd | |
| 650 | 1 | 7 | |a Farmaceutische industrie. |2 gtt |
| 650 | 1 | 7 | |a Onderzoek. |2 gtt |
| 650 | 1 | 7 | |a Keuzes. |2 gtt |
| 700 | 1 | |a Glennerster, Rachel. | |
| 776 | 0 | 8 | |i Print version: |a Kremer, Michael, 1964- |t Strong medicine. |d Princeton, NJ : Princeton University Press, 2004 |z 0691121133 |w (DLC) 2004050384 |w (OCoLC)55596208 |
| 856 | 4 | 0 | |u https://jstor.uam.elogim.com/stable/10.2307/j.ctt1dr365r |z Texto completo |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL4333578 | ||
| 938 | |a EBSCOhost |b EBSC |n 1141350 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n cis34172277 | ||
| 938 | |a Internet Archive |b INAR |n strongmedicinecr0000krem | ||
| 938 | |a Project MUSE |b MUSE |n muse55881 | ||
| 938 | |a YBP Library Services |b YANK |n 12758922 | ||
| 994 | |a 92 |b IZTAP | ||